DrugPatentWatch Database Preview
ONZETRA XSAIL Drug Profile
When do Onzetra Xsail patents expire, and when can generic versions of Onzetra Xsail launch?
Onzetra Xsail is a drug marketed by Currax and is included in one NDA. There are seventeen patents protecting this drug.
This drug has two hundred and fifty-one patent family members in twenty-eight countries.
The generic ingredient in ONZETRA XSAIL is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
Summary for ONZETRA XSAIL
| International Patents: | 251 |
| US Patents: | 17 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 45 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,043 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ONZETRA XSAIL |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ONZETRA XSAIL |
| DailyMed Link: | ONZETRA XSAIL at DailyMed |
Recent Clinical Trials for ONZETRA XSAIL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Avanir Pharmaceuticals | Phase 3 |
Recent Litigation for ONZETRA XSAIL
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| ADAMAS PHARMA, LLC v. SANDOZ INC. | 2018-05-10 |
Synonyms for ONZETRA XSAIL
| (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide |
| (3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide # |
| 1-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide |
| 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide |
| 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide |
| 1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methyl-methanesulfonamide |
| 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide |
| 103628-46-2 |
| 103628-48-4 (succinate) |
| 1H-Indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-N-methyl- |
| 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide |
| 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole -5-methanesulphonamide |
| 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide |
| 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide |
| 3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide |
| 628S462 |
| 8R78F6L9VO |
| AB0016356 |
| AB00698285_14 |
| AB00698285_15 |
| AB00698285-12 |
| AB00698285-13 |
| AC1L1K6B |
| AJ-08373 |
| AKOS015894924 |
| AN-5271 |
| API0004291 |
| AVP 825 |
| AVP-825 |
| AVP825 |
| BCP02237 |
| BDBM50005835 |
| BIDD:GT0248 |
| BRD-K50938287-001-01-7 |
| BRN 6930870 |
| BSPBio_002304 |
| C07319 |
| C14H21N3O2S |
| CAS-103628-46-2 |
| CCG-230331 |
| CHEBI:10650 |
| CHEMBL128 |
| D00451 |
| DB00669 |
| DSSTox_CID_3628 |
| DSSTox_GSID_23628 |
| DSSTox_RID_77118 |
| DTXSID4023628 |
| FT-0631027 |
| GR 43175 |
| GR 43175X |
| GR-43175 |
| GTPL54 |
| HMS2231B21 |
| HMS3369A05 |
| HSDB 7742 |
| I06-0076 |
| Imigran (TN) |
| Imigran Recovery |
| Imitrex (TN) |
| Imitrex Oral |
| Imitrex, Imigran ,Treximet |
| J-001014 |
| KB-217141 |
| KQKPFRSPSRPDEB-UHFFFAOYSA-N |
| L000584 |
| LS-83175 |
| MCULE-3991948648 |
| MLS001195659 |
| MLS001304742 |
| MolPort-002-885-863 |
| NCGC00095838-01 |
| NCGC00095838-02 |
| NCGC00095838-03 |
| NCGC00095838-04 |
| O262 |
| SBI-0206837.P001 |
| SC-18016 |
| SCHEMBL1482 |
| SMR000596517 |
| SPECTRUM1505372 |
| STL451003 |
| Sumatran |
| sumatriptan |
| Sumatriptan (JAN/USP/INN) |
| Sumatriptan [USP:INN:BAN] |
| Sumatriptanum |
| Sumatriptanum [INN-Latin] |
| Sumax |
| Tox21_111528 |
| Tox21_111528_1 |
| UNII-8R78F6L9VO |
| Zecuity |
| Zembrace SymTouch |
| ZINC14360 |
US Patents and Regulatory Information for ONZETRA XSAIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Currax | ONZETRA XSAIL | sumatriptan succinate | POWDER;NASAL | 206099-001 | Jan 27, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ONZETRA XSAIL
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 1736502 | Start Trial |
| European Patent Office | 1399203 | Start Trial |
| Japan | 2010179168 | Start Trial |
| Turkey | 200102563 | Start Trial |
| United Kingdom | 0005254 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
